TrialMultiple sclerosis (Houndmills, Basingstoke, England)2022

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.

Sean J Pittock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.